Stockreport

Sage Announces Pivotal Phase 3 Trial Status for SAGE-217 in Major Depressive Disorder and Postpartum Depression based on FDA Breakthrough Therapy Meeting

Sage Therapeutics, Inc.  (SAGE) 
Last sage therapeutics, inc. earnings: 2/27 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.sagerx.com/investor-relations
PDF Expedited SAGE-217 development plan to support potential NDA submission for MDD and PPD Previously completed placebo-controlled study in MDD cons [Read more]